Literature DB >> 16325969

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.

Sima Rafati1, Farnaz Zahedifard, Fereshteh Nazgouee.   

Abstract

Vaccination with a cocktail of DNA encoding cysteine proteinases has been previously shown to confer protection against experimental cutaneous leishmaniasis (CL). In the present study we test the efficacy of immunization against Leishmania infantum in a murine model of infection, using a prime-boost strategy. BALB/c mice were immunized twice, in a 3 weeks interval, with cocktail of plasmids DNA encoding type I (cpb) and II (cpa) cysteine proteinases. DNA immunization was then followed by a boost with rCPA/rCPB in addition to CpG ODN and Montanide720 as adjuvant. Analysis of the immune response showed that vaccination mainly elicited antigen-specific IgG2a antibodies, suggesting the induction of a Th1 immune response. This was further confirmed by the analysis of the splenic cytokine production: at all time points the ratio of IFN-gamma/IL-5 induced upon restimulation with rCPA and rCPB was always significantly higher in vaccinated group compared to both control groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325969     DOI: 10.1016/j.vaccine.2005.11.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

3.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

4.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

5.  Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine.

Authors:  Rajiv Kumar; Yasuyuki Goto; Kamlesh Gidwani; Karen D Cowgill; Shyam Sundar; Steven G Reed
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

6.  Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major.

Authors:  Somayeh Zarrati; Mehdi Mahdavi; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-08-31

Review 7.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

Review 8.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

9.  Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Authors:  Yasuyuki Goto; Randall F Howard; Ajay Bhatia; Joelma Trigo; Maria Nakatani; Eduardo M Netto; Steven G Reed
Journal:  Vet Parasitol       Date:  2008-11-05       Impact factor: 2.738

10.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.